Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers February 15, 2019
Pharmacy Choice - Pharmaceutical News - Kiadis Pharma to participate in a panel at Innovation for Health 2019 - February 15, 2019

Pharmacy News Article

 2/11/19 - Kiadis Pharma to participate in a panel at Innovation for Health 2019

     Kiadis Pharma to participate in a panel at Innovation for Health 2019

Amsterdam,  The  Netherlands,  February  11, 2019 -  Kiadis Pharma N.V. ("Kiadis
Pharma"  or the "Company")  (Euronext Amsterdam and  Brussels: KDS), a clinical-
stage  biopharmaceutical  company,  today  announces  that  it  is  scheduled to
participate  in a panel at the  Innovation for Health 2019 Conference and Global
Investor Forum on Thursday, February 14, 2019.

Innovation for Health
February  14, 2019, World Trade Center  Rotterdam, Beursplein 37, Rotterdam, The
Arthur  Lahr, Chief  Executive Officer,  will participate  in a panel discussion
related to "Building a Winning Team for Innovation" held from 13:30 - 14:30 CET.

Innovation for Health is one of the premier events for Health & Life Sciences in
the  Netherlands and Belgium. It brings together key players in health and care,
from  bench to  boardroom, start-up  to multinational  and from life sciences to
medtech.  Held in conjunction with Global  Investor Forum, Innovation for Health
brings  together  over  800 delegates  and  60 influential  speakers from across
industry,  academia,  government,  finance  and  patient-organisations  with the
purpose to contribute to a sustainable future of healthcare.

For more information, please contact:

 Kiadis Pharma:                        Optimum Strategic Communications:
 Amy Sullivan                          Mary Clark, Supriya Mathur, Hollie Vile
 Sr. Vice President, Corporate Affairs Tel: +44 203 950 9144                 David Brilleslijper (Amsterdam)
                                      Tel: +31 610 942 514

About Kiadis Pharma
Kiadis  Pharma is  developing its  lead product  candidate, ATIR101,  for use in
conjunction  with haploidentical (genetically  half-matched) hematopoietic stem-
cell  transplantations (HSCT) for adult blood cancers to address key limitations
of   haploidentical   HSCT,   without  prophylactic  immunosuppression  and  its
associated  morbidity  and  mortality.  Based  on  the positive results from the
single   dose  Phase  2 CR-AIR-007 study,  the  Company  submitted  a  marketing
authorization  application to  the European  Medicines Agency  in April 2017 for
approval  of ATIR101 as an adjunctive  treatment in haploidentical HSCT for high
risk adult hematological malignancies. If the product is conditionally approved,
Kiadis  Pharma intends to launch ATIR101 through its own commercial organization
in a first EU member state in the second half of 2019.

In   December  2017, Kiadis  Pharma  commenced  an  international,  multicenter,
randomized  and controlled Phase  3 clinical trial of  ATIR101 against the Post-
Transplant  Cyclophosphamide, (PTCy) protocol, the main protocol used to perform
a  haploidentical HSCT. The  trial will be  performed in 250 patients with acute
leukemia  and myelodysplastic syndrome  at approximately 50 sites  in the United
States,  Canada,  Europe  and  certain  additional  countries.  ATIR101 received
regenerative  medicine  advanced  therapy  (RMAT)  designation  from  the FDA in
September  2017, which  provides  benefits  that  are materially equivalent to a
Breakthrough  Therapy designation  from the  FDA. In  addition, ATIR101 has been
granted  multiple orphan  drug designations  both in  the European Union and the
United States.

The  Company's shares  are listed  on Euronext  Amsterdam and Brussels under the
ticker KDS.

Forward Looking Statements
Certain  statements, beliefs  and opinions  in this  press release  are forward-
looking,  which  reflect  Kiadis  Pharma's  or,  as appropriate, Kiadis Pharma's
directors'  current expectations and  projections about future  events. By their
nature,  forward-looking statements involve a number of risks, uncertainties and
assumptions  that could cause actual results or events to differ materially from
those  expressed  or  implied  by  the  forward-looking statements. These risks,
uncertainties  and assumptions could adversely  affect the outcome and financial
effects  of  the  plans  and  events  described  herein.  A multitude of factors
including,  but not limited  to, changes in  demand, regulation, competition and
technology,   can   cause  actual  events,  performance  or  results  to  differ
significantly  from  any  anticipated  development.  Forward  looking statements
contained  in this press release regarding  past trends or activities should not
be taken as a representation that such trends or activities will continue in the
future.  As  a  result,  Kiadis  Pharma  expressly  disclaims  any obligation or
undertaking to release any update or revisions to any forward-looking statements
in this press release as a result of any change in expectations or any change in
events,  conditions, assumptions or circumstances on which these forward-looking
statements  are based. Neither Kiadis Pharma nor its advisers or representatives
nor  any  of  its  subsidiary  undertakings  or  any  such  person's officers or
employees  guarantees  that  the  assumptions  underlying  such  forward-looking
statements  are free from  errors nor does  either accept any responsibility for
the  future accuracy of  the forward-looking statements  contained in this press
release  or the actual occurrence of the forecasted developments. You should not
place  undue reliance on forward-looking statements,  which speak only as of the
date of this press release.

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Kiadis Pharma N. V. via GlobeNewswire


Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Feb 18: Management of Schizophrenia & Acute Agitation
Feb 19: Treatment of Atopic Dermatitis (Eczema) & Xerosis (Dry Skin)
Feb 20: Know Your Value, Know Your Worth: Provider Status in Pharmacy
Feb 21: Type II Diabetes: Case Studies and Management Options
Feb 22: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement